drugset / Trial / NCT00412854

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

NCT00412854 ↗

Phase 3 Completed 660 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will compare GSK Biologicals' DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese infants 3, 4 \& 5 months of age, in terms of safety and immunogenicity.

Timeline

Start
2007-01-03
Primary completion
2007-06-01
Completion
2007-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN Vaccine — —
Subject Infanrix Vaccine — —
Subject Infanrix/Hib Vaccine — —

Indications